Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study.
D Tripathy, M Carlsson, P Almgren, B Isomaa… - Diabetes, 2000 - Am Diabetes Assoc
D Tripathy, M Carlsson, P Almgren, B Isomaa, MR Taskinen, T Tuomi, LC Groop
Diabetes, 2000•Am Diabetes AssocRecently, a new stage in glucose tolerance, impaired fasting glucose (IFG)(fasting plasma
glucose level of 6.1-6.9 mmol/l), was introduced in addition to impaired glucose tolerance
(IGT)(2-h glucose level of 7.8-11.0 mmol/l). It is not clear whether IFG and IGT differ with
respect to insulin secretion or sensitivity. To address this question, we estimated insulin
secretion (by measuring both insulin levels and the ratio of insulin-to-glucose levels in 30-
min intervals) and insulin sensitivity (by using the homeostasis model assessment [HOMA] …
glucose level of 6.1-6.9 mmol/l), was introduced in addition to impaired glucose tolerance
(IGT)(2-h glucose level of 7.8-11.0 mmol/l). It is not clear whether IFG and IGT differ with
respect to insulin secretion or sensitivity. To address this question, we estimated insulin
secretion (by measuring both insulin levels and the ratio of insulin-to-glucose levels in 30-
min intervals) and insulin sensitivity (by using the homeostasis model assessment [HOMA] …
Recently, a new stage in glucose tolerance, impaired fasting glucose (IFG) (fasting plasma glucose level of 6.1-6.9 mmol/l), was introduced in addition to impaired glucose tolerance (IGT) (2-h glucose level of 7.8-11.0 mmol/l). It is not clear whether IFG and IGT differ with respect to insulin secretion or sensitivity. To address this question, we estimated insulin secretion (by measuring both insulin levels and the ratio of insulin-to-glucose levels in 30-min intervals) and insulin sensitivity (by using the homeostasis model assessment [HOMA] index) from an oral glucose tolerance test (OGTT) in 5,396 individuals from the Botnia Study who had varying degrees of glucose tolerance. There was poor concordance between IFG and IGT: only 36% (303 of 840) of the subjects with IFG had IGT, whereas 62% (493 of 796) of the subjects with IGT did not have IFG. Compared with subjects with normal glucose tolerance (NGT), subjects with IFG were more insulin resistant (HOMA-insulin resistance [IR] values 2.64 +/- 0.08 vs. 1.73 +/- 0.03, P < 0.0005), had greater insulin responses during an OGTT (P = 0.0001), had higher waist-to-hip ratios (P < 0.005), had higher triglyceride and total cholesterol concentrations (P < 0.0005), and had lower HDL cholesterol concentrations (P = 0.0001). Compared with subjects with IFG, subjects with IGT had a lower incremental 30-min insulin-to-glucose area during an OGTT (13.8 +/- 1.7 vs. 21.7 +/- 1.7, P = 0.0008). Compared with subjects with IGT, subjects with mild diabetes (fasting plasma glucose levels <7.8 mmol/l) showed markedly impaired insulin secretion that could no longer compensate for IR and elevated glucose levels. A progressive decline in insulin sensitivity was observed when moving from NGT to IGT and to subjects with diabetes (P < 0.05 for trend), whereas insulin secretion followed an inverted U-shaped form. We conclude that IFG is characterized by basal IR and other features of the metabolic syndrome, whereas subjects with IGT have impaired insulin secretion in relation to glucose concentrations. An absolute decompensation of beta-cell function characterizes the transition from IGT to mild diabetes.
Am Diabetes Assoc